nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2D6—Lomustine—brain cancer	0.125	0.303	CbGbCtD
Atomoxetine—CYP2D6—Hydroxyurea—brain cancer	0.0946	0.23	CbGbCtD
Atomoxetine—CYP3A4—Temozolomide—brain cancer	0.0933	0.227	CbGbCtD
Atomoxetine—CYP3A4—Lomustine—brain cancer	0.0794	0.193	CbGbCtD
Atomoxetine—HTR1D—meninx—brain cancer	0.0239	0.0811	CbGeAlD
Atomoxetine—HTR1B—dura mater—brain cancer	0.0228	0.077	CbGeAlD
Atomoxetine—HTR1D—dura mater—brain cancer	0.022	0.0746	CbGeAlD
Atomoxetine—CYP3A4—Etoposide—brain cancer	0.0192	0.0466	CbGbCtD
Atomoxetine—HTR2C—choroid plexus—brain cancer	0.0186	0.0628	CbGeAlD
Atomoxetine—HTR1B—trigeminal nerve—brain cancer	0.00978	0.0331	CbGeAlD
Atomoxetine—HTR1D—trigeminal nerve—brain cancer	0.00947	0.0321	CbGeAlD
Atomoxetine—HTR2A—choroid plexus—brain cancer	0.00931	0.0315	CbGeAlD
Atomoxetine—HTR1B—cranial nerve—brain cancer	0.00697	0.0236	CbGeAlD
Atomoxetine—HTR1D—cranial nerve—brain cancer	0.00675	0.0229	CbGeAlD
Atomoxetine—HTR6—ganglion—brain cancer	0.00585	0.0198	CbGeAlD
Atomoxetine—HTR1B—telencephalic ventricle—brain cancer	0.00567	0.0192	CbGeAlD
Atomoxetine—SLC6A3—telencephalic ventricle—brain cancer	0.00562	0.019	CbGeAlD
Atomoxetine—HTR1D—telencephalic ventricle—brain cancer	0.00549	0.0186	CbGeAlD
Atomoxetine—HTR2C—telencephalic ventricle—brain cancer	0.00543	0.0184	CbGeAlD
Atomoxetine—HTR2A—trigeminal nerve—brain cancer	0.00471	0.0159	CbGeAlD
Atomoxetine—HTR2A—cerebellar cortex—brain cancer	0.00469	0.0159	CbGeAlD
Atomoxetine—HTR2A—vein—brain cancer	0.00425	0.0144	CbGeAlD
Atomoxetine—Epigastric discomfort—Hydroxyurea—brain cancer	0.00372	0.0171	CcSEcCtD
Atomoxetine—HTR1B—ganglion—brain cancer	0.00353	0.0119	CbGeAlD
Atomoxetine—SLC6A3—ganglion—brain cancer	0.0035	0.0118	CbGeAlD
Atomoxetine—HTR1D—ganglion—brain cancer	0.00342	0.0116	CbGeAlD
Atomoxetine—HTR2C—ganglion—brain cancer	0.00338	0.0115	CbGeAlD
Atomoxetine—HTR2A—cranial nerve—brain cancer	0.00335	0.0114	CbGeAlD
Atomoxetine—Gastrointestinal symptom NOS—Hydroxyurea—brain cancer	0.00333	0.0153	CcSEcCtD
Atomoxetine—HTR2A—pons—brain cancer	0.00331	0.0112	CbGeAlD
Atomoxetine—Disorientation—Lomustine—brain cancer	0.00323	0.0149	CcSEcCtD
Atomoxetine—NPY1R—telencephalon—brain cancer	0.00321	0.0109	CbGeAlD
Atomoxetine—SLC6A4—ganglion—brain cancer	0.00321	0.0109	CbGeAlD
Atomoxetine—Lethargy—Lomustine—brain cancer	0.00295	0.0136	CcSEcCtD
Atomoxetine—SLC6A2—ganglion—brain cancer	0.00282	0.00956	CbGeAlD
Atomoxetine—HTR1B—blood vessel—brain cancer	0.00281	0.0095	CbGeAlD
Atomoxetine—HTR2A—telencephalic ventricle—brain cancer	0.00273	0.00923	CbGeAlD
Atomoxetine—HTR1D—blood vessel—brain cancer	0.00272	0.0092	CbGeAlD
Atomoxetine—NPY1R—gonad—brain cancer	0.00268	0.00907	CbGeAlD
Atomoxetine—SLC6A3—hindbrain—brain cancer	0.00265	0.00899	CbGeAlD
Atomoxetine—NPY1R—pituitary gland—brain cancer	0.00261	0.00885	CbGeAlD
Atomoxetine—SLC6A4—hindbrain—brain cancer	0.00243	0.00823	CbGeAlD
Atomoxetine—HTR2A—pineal body—brain cancer	0.00237	0.00801	CbGeAlD
Atomoxetine—Coma—Procarbazine—brain cancer	0.00231	0.0106	CcSEcCtD
Atomoxetine—HTR6—telencephalon—brain cancer	0.00226	0.00765	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—brain cancer	0.00205	0.192	CrCbGaD
Atomoxetine—Disorientation—Procarbazine—brain cancer	0.00205	0.00945	CcSEcCtD
Atomoxetine—NPY1R—endocrine gland—brain cancer	0.00202	0.00685	CbGeAlD
Atomoxetine—NPY1R—head—brain cancer	0.002	0.00676	CbGeAlD
Atomoxetine—Lethargy—Procarbazine—brain cancer	0.00187	0.00863	CcSEcCtD
Atomoxetine—Rigors—Temozolomide—brain cancer	0.00187	0.00863	CcSEcCtD
Atomoxetine—NPY1R—central nervous system—brain cancer	0.00182	0.00617	CbGeAlD
Atomoxetine—Drug interaction—Carmustine—brain cancer	0.0017	0.00786	CcSEcCtD
Atomoxetine—HTR2A—ganglion—brain cancer	0.0017	0.00575	CbGeAlD
Atomoxetine—Infection—Carboplatin—brain cancer	0.00161	0.00743	CcSEcCtD
Atomoxetine—Disorientation—Hydroxyurea—brain cancer	0.00159	0.00731	CcSEcCtD
Atomoxetine—Hepatic failure—Hydroxyurea—brain cancer	0.00158	0.00728	CcSEcCtD
Atomoxetine—Sweating increased—Procarbazine—brain cancer	0.00154	0.00712	CcSEcCtD
Atomoxetine—HTR1B—brainstem—brain cancer	0.00153	0.00519	CbGeAlD
Atomoxetine—SLC6A3—brainstem—brain cancer	0.00152	0.00515	CbGeAlD
Atomoxetine—Rigors—Etoposide—brain cancer	0.0015	0.0069	CcSEcCtD
Atomoxetine—HTR1D—brainstem—brain cancer	0.00148	0.00503	CbGeAlD
Atomoxetine—HTR2C—brainstem—brain cancer	0.00147	0.00498	CbGeAlD
Atomoxetine—Pollakiuria—Procarbazine—brain cancer	0.00146	0.00675	CcSEcCtD
Atomoxetine—HTR2A—endothelium—brain cancer	0.00146	0.00495	CbGeAlD
Atomoxetine—NPY1R—brain—brain cancer	0.00145	0.0049	CbGeAlD
Atomoxetine—Coma—Carmustine—brain cancer	0.00144	0.00666	CcSEcCtD
Atomoxetine—Infection—Lomustine—brain cancer	0.00141	0.0065	CcSEcCtD
Atomoxetine—HTR6—head—brain cancer	0.00141	0.00476	CbGeAlD
Atomoxetine—SLC6A4—brainstem—brain cancer	0.00139	0.00472	CbGeAlD
Atomoxetine—Pain—Carboplatin—brain cancer	0.00139	0.0064	CcSEcCtD
Atomoxetine—HTR1B—telencephalon—brain cancer	0.00136	0.00461	CbGeAlD
Atomoxetine—Anorexia—Lomustine—brain cancer	0.00135	0.00624	CcSEcCtD
Atomoxetine—SLC6A3—telencephalon—brain cancer	0.00135	0.00457	CbGeAlD
Atomoxetine—HTR2A—blood vessel—brain cancer	0.00135	0.00457	CbGeAlD
Atomoxetine—HTR1D—telencephalon—brain cancer	0.00132	0.00446	CbGeAlD
Atomoxetine—HTR2C—telencephalon—brain cancer	0.0013	0.00442	CbGeAlD
Atomoxetine—HTR2A—hindbrain—brain cancer	0.00129	0.00436	CbGeAlD
Atomoxetine—HTR6—central nervous system—brain cancer	0.00128	0.00435	CbGeAlD
Atomoxetine—Body temperature increased—Carboplatin—brain cancer	0.00128	0.00591	CcSEcCtD
Atomoxetine—Breast disorder—Hydroxyurea—brain cancer	0.00128	0.00591	CcSEcCtD
Atomoxetine—Hallucination—Procarbazine—brain cancer	0.00126	0.00582	CcSEcCtD
Atomoxetine—SLC6A4—telencephalon—brain cancer	0.00124	0.00419	CbGeAlD
Atomoxetine—Decreased appetite—Lomustine—brain cancer	0.00123	0.00569	CcSEcCtD
Atomoxetine—Hepatic failure—Temozolomide—brain cancer	0.00123	0.00569	CcSEcCtD
Atomoxetine—SLC6A2—brainstem—brain cancer	0.00123	0.00416	CbGeAlD
Atomoxetine—Nasal congestion—Temozolomide—brain cancer	0.00122	0.00561	CcSEcCtD
Atomoxetine—Hot flush—Temozolomide—brain cancer	0.00119	0.00546	CcSEcCtD
Atomoxetine—Flushing—Procarbazine—brain cancer	0.00118	0.00543	CcSEcCtD
Atomoxetine—Menopausal symptoms—Temozolomide—brain cancer	0.00118	0.00542	CcSEcCtD
Atomoxetine—CYP2D6—hindbrain—brain cancer	0.00117	0.00397	CbGeAlD
Atomoxetine—Thirst—Temozolomide—brain cancer	0.00117	0.00537	CcSEcCtD
Atomoxetine—Dysuria—Hydroxyurea—brain cancer	0.00115	0.00529	CcSEcCtD
Atomoxetine—Chills—Procarbazine—brain cancer	0.00114	0.00525	CcSEcCtD
Atomoxetine—Body temperature increased—Lomustine—brain cancer	0.00112	0.00517	CcSEcCtD
Atomoxetine—Infestation NOS—Hydroxyurea—brain cancer	0.00109	0.00504	CcSEcCtD
Atomoxetine—Infestation—Hydroxyurea—brain cancer	0.00109	0.00504	CcSEcCtD
Atomoxetine—Affect lability—Temozolomide—brain cancer	0.00109	0.00503	CcSEcCtD
Atomoxetine—SLC6A2—telencephalon—brain cancer	0.00109	0.00369	CbGeAlD
Atomoxetine—Tension—Procarbazine—brain cancer	0.00108	0.005	CcSEcCtD
Atomoxetine—Nervousness—Procarbazine—brain cancer	0.00107	0.00495	CcSEcCtD
Atomoxetine—Mood swings—Temozolomide—brain cancer	0.00105	0.00484	CcSEcCtD
Atomoxetine—Tremor—Procarbazine—brain cancer	0.00104	0.00477	CcSEcCtD
Atomoxetine—HTR2C—medulla oblongata—brain cancer	0.00103	0.00347	CbGeAlD
Atomoxetine—Cyclizine—CYP2C9—brain cancer	0.00102	0.0955	CrCbGaD
Atomoxetine—HTR6—brain—brain cancer	0.00102	0.00345	CbGeAlD
Atomoxetine—Tolterodine—CYP2C9—brain cancer	0.00101	0.0945	CrCbGaD
Atomoxetine—Breast disorder—Temozolomide—brain cancer	0.001	0.00462	CcSEcCtD
Atomoxetine—Phenprocoumon—CYP2C9—brain cancer	0.000994	0.0927	CrCbGaD
Atomoxetine—Syncope—Procarbazine—brain cancer	0.000991	0.00457	CcSEcCtD
Atomoxetine—HTR1B—midbrain—brain cancer	0.000977	0.00331	CbGeAlD
Atomoxetine—Hallucination—Hydroxyurea—brain cancer	0.000977	0.0045	CcSEcCtD
Atomoxetine—Loss of consciousness—Procarbazine—brain cancer	0.000971	0.00448	CcSEcCtD
Atomoxetine—SLC6A3—midbrain—brain cancer	0.000969	0.00328	CbGeAlD
Atomoxetine—Fluoxetine—CYP2C9—brain cancer	0.000967	0.0901	CrCbGaD
Atomoxetine—Cough—Procarbazine—brain cancer	0.000964	0.00444	CcSEcCtD
Atomoxetine—Convulsion—Procarbazine—brain cancer	0.000957	0.00441	CcSEcCtD
Atomoxetine—HTR1B—spinal cord—brain cancer	0.000954	0.00323	CbGeAlD
Atomoxetine—HTR1D—midbrain—brain cancer	0.000946	0.0032	CbGeAlD
Atomoxetine—SLC6A3—spinal cord—brain cancer	0.000946	0.0032	CbGeAlD
Atomoxetine—Arthralgia—Procarbazine—brain cancer	0.000941	0.00433	CcSEcCtD
Atomoxetine—Myalgia—Procarbazine—brain cancer	0.000941	0.00433	CcSEcCtD
Atomoxetine—Anxiety—Procarbazine—brain cancer	0.000937	0.00432	CcSEcCtD
Atomoxetine—HTR2C—midbrain—brain cancer	0.000937	0.00317	CbGeAlD
Atomoxetine—Sweating increased—Temozolomide—brain cancer	0.000934	0.0043	CcSEcCtD
Atomoxetine—Dry mouth—Procarbazine—brain cancer	0.00092	0.00424	CcSEcCtD
Atomoxetine—HTR2C—spinal cord—brain cancer	0.000914	0.0031	CbGeAlD
Atomoxetine—SLC6A2—gonad—brain cancer	0.000909	0.00308	CbGeAlD
Atomoxetine—Vomiting—Lomustine—brain cancer	0.000903	0.00416	CcSEcCtD
Atomoxetine—Dysuria—Temozolomide—brain cancer	0.000897	0.00413	CcSEcCtD
Atomoxetine—Infection—Procarbazine—brain cancer	0.000896	0.00413	CcSEcCtD
Atomoxetine—Angiopathy—Hydroxyurea—brain cancer	0.000891	0.00411	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Temozolomide—brain cancer	0.000891	0.00411	CcSEcCtD
Atomoxetine—SLC6A4—midbrain—brain cancer	0.000888	0.00301	CbGeAlD
Atomoxetine—Shock—Procarbazine—brain cancer	0.000887	0.00409	CcSEcCtD
Atomoxetine—Pollakiuria—Temozolomide—brain cancer	0.000886	0.00408	CcSEcCtD
Atomoxetine—Erectile dysfunction—Temozolomide—brain cancer	0.000883	0.00407	CcSEcCtD
Atomoxetine—Depression—Carmustine—brain cancer	0.000882	0.00406	CcSEcCtD
Atomoxetine—Warfarin—CYP2C9—brain cancer	0.000881	0.0822	CrCbGaD
Atomoxetine—Chills—Hydroxyurea—brain cancer	0.000881	0.00406	CcSEcCtD
Atomoxetine—Tachycardia—Procarbazine—brain cancer	0.00088	0.00406	CcSEcCtD
Atomoxetine—Hyperhidrosis—Procarbazine—brain cancer	0.000872	0.00402	CcSEcCtD
Atomoxetine—Weight decreased—Temozolomide—brain cancer	0.000867	0.004	CcSEcCtD
Atomoxetine—SLC6A4—spinal cord—brain cancer	0.000867	0.00293	CbGeAlD
Atomoxetine—Propafenone—CYP2C9—brain cancer	0.000862	0.0803	CrCbGaD
Atomoxetine—Anorexia—Procarbazine—brain cancer	0.00086	0.00396	CcSEcCtD
Atomoxetine—HTR1B—endocrine gland—brain cancer	0.000859	0.00291	CbGeAlD
Atomoxetine—SLC6A2—medulla oblongata—brain cancer	0.000856	0.0029	CbGeAlD
Atomoxetine—Infestation NOS—Temozolomide—brain cancer	0.000855	0.00394	CcSEcCtD
Atomoxetine—Infestation—Temozolomide—brain cancer	0.000855	0.00394	CcSEcCtD
Atomoxetine—Depression—Temozolomide—brain cancer	0.000852	0.00393	CcSEcCtD
Atomoxetine—HTR1B—head—brain cancer	0.000848	0.00287	CbGeAlD
Atomoxetine—Nausea—Lomustine—brain cancer	0.000844	0.00389	CcSEcCtD
Atomoxetine—SLC6A3—head—brain cancer	0.000841	0.00285	CbGeAlD
Atomoxetine—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000822	0.00379	CcSEcCtD
Atomoxetine—HTR1D—head—brain cancer	0.000821	0.00278	CbGeAlD
Atomoxetine—Insomnia—Procarbazine—brain cancer	0.000816	0.00376	CcSEcCtD
Atomoxetine—HTR2C—head—brain cancer	0.000813	0.00275	CbGeAlD
Atomoxetine—Paraesthesia—Procarbazine—brain cancer	0.00081	0.00373	CcSEcCtD
Atomoxetine—Sinusitis—Temozolomide—brain cancer	0.000802	0.0037	CcSEcCtD
Atomoxetine—Somnolence—Procarbazine—brain cancer	0.000802	0.00369	CcSEcCtD
Atomoxetine—Hallucination—Carmustine—brain cancer	0.00079	0.00364	CcSEcCtD
Atomoxetine—Hypoaesthesia—Carmustine—brain cancer	0.00079	0.00364	CcSEcCtD
Atomoxetine—Decreased appetite—Procarbazine—brain cancer	0.000784	0.00361	CcSEcCtD
Atomoxetine—SLC6A4—endocrine gland—brain cancer	0.00078	0.00264	CbGeAlD
Atomoxetine—Fatigue—Procarbazine—brain cancer	0.000777	0.00358	CcSEcCtD
Atomoxetine—HTR1B—central nervous system—brain cancer	0.000774	0.00262	CbGeAlD
Atomoxetine—Constipation—Procarbazine—brain cancer	0.000771	0.00355	CcSEcCtD
Atomoxetine—Pain—Procarbazine—brain cancer	0.000771	0.00355	CcSEcCtD
Atomoxetine—SLC6A4—head—brain cancer	0.00077	0.00261	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—brain cancer	0.000767	0.0026	CbGeAlD
Atomoxetine—Hypoaesthesia—Temozolomide—brain cancer	0.000764	0.00352	CcSEcCtD
Atomoxetine—Hallucination—Temozolomide—brain cancer	0.000764	0.00352	CcSEcCtD
Atomoxetine—Urinary tract disorder—Temozolomide—brain cancer	0.000758	0.00349	CcSEcCtD
Atomoxetine—Urethral disorder—Temozolomide—brain cancer	0.000752	0.00347	CcSEcCtD
Atomoxetine—SLC6A3—cerebellum—brain cancer	0.00075	0.00254	CbGeAlD
Atomoxetine—HTR1D—central nervous system—brain cancer	0.000749	0.00254	CbGeAlD
Atomoxetine—Sweating increased—Etoposide—brain cancer	0.000747	0.00344	CcSEcCtD
Atomoxetine—Feeling abnormal—Procarbazine—brain cancer	0.000743	0.00342	CcSEcCtD
Atomoxetine—HTR2C—central nervous system—brain cancer	0.000742	0.00251	CbGeAlD
Atomoxetine—Convulsion—Hydroxyurea—brain cancer	0.000741	0.00341	CcSEcCtD
Atomoxetine—HTR2A—brainstem—brain cancer	0.000738	0.0025	CbGeAlD
Atomoxetine—Gastrointestinal pain—Procarbazine—brain cancer	0.000737	0.0034	CcSEcCtD
Atomoxetine—Flushing—Carmustine—brain cancer	0.000737	0.0034	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000723	0.00333	CcSEcCtD
Atomoxetine—Modafinil—CYP2C9—brain cancer	0.000722	0.0673	CrCbGaD
Atomoxetine—Urticaria—Procarbazine—brain cancer	0.000716	0.0033	CcSEcCtD
Atomoxetine—Abdominal pain—Procarbazine—brain cancer	0.000713	0.00329	CcSEcCtD
Atomoxetine—Body temperature increased—Procarbazine—brain cancer	0.000713	0.00329	CcSEcCtD
Atomoxetine—Cardiac disorder—Temozolomide—brain cancer	0.000712	0.00328	CcSEcCtD
Atomoxetine—Flushing—Temozolomide—brain cancer	0.000712	0.00328	CcSEcCtD
Atomoxetine—SLC6A4—central nervous system—brain cancer	0.000703	0.00238	CbGeAlD
Atomoxetine—Angiopathy—Temozolomide—brain cancer	0.000696	0.00321	CcSEcCtD
Atomoxetine—Mental disorder—Carmustine—brain cancer	0.000696	0.00321	CcSEcCtD
Atomoxetine—Infection—Hydroxyurea—brain cancer	0.000693	0.0032	CcSEcCtD
Atomoxetine—Mediastinal disorder—Temozolomide—brain cancer	0.000692	0.00319	CcSEcCtD
Atomoxetine—Malnutrition—Carmustine—brain cancer	0.000691	0.00319	CcSEcCtD
Atomoxetine—Chills—Temozolomide—brain cancer	0.000689	0.00317	CcSEcCtD
Atomoxetine—SLC6A2—endocrine gland—brain cancer	0.000687	0.00233	CbGeAlD
Atomoxetine—Nervous system disorder—Hydroxyurea—brain cancer	0.000684	0.00315	CcSEcCtD
Atomoxetine—Infestation NOS—Etoposide—brain cancer	0.000684	0.00315	CcSEcCtD
Atomoxetine—Infestation—Etoposide—brain cancer	0.000684	0.00315	CcSEcCtD
Atomoxetine—Ketoprofen—CYP2C9—brain cancer	0.00068	0.0634	CrCbGaD
Atomoxetine—SLC6A2—head—brain cancer	0.000678	0.0023	CbGeAlD
Atomoxetine—Skin disorder—Hydroxyurea—brain cancer	0.000678	0.00312	CcSEcCtD
Atomoxetine—Mental disorder—Temozolomide—brain cancer	0.000672	0.0031	CcSEcCtD
Atomoxetine—CYP2D6—brainstem—brain cancer	0.000672	0.00228	CbGeAlD
Atomoxetine—Back pain—Carmustine—brain cancer	0.000669	0.00308	CcSEcCtD
Atomoxetine—Malnutrition—Temozolomide—brain cancer	0.000668	0.00308	CcSEcCtD
Atomoxetine—Anorexia—Hydroxyurea—brain cancer	0.000665	0.00307	CcSEcCtD
Atomoxetine—HTR2A—telencephalon—brain cancer	0.000655	0.00222	CbGeAlD
Atomoxetine—Dysgeusia—Temozolomide—brain cancer	0.000654	0.00301	CcSEcCtD
Atomoxetine—Vision blurred—Carmustine—brain cancer	0.000651	0.003	CcSEcCtD
Atomoxetine—Tremor—Carmustine—brain cancer	0.000648	0.00298	CcSEcCtD
Atomoxetine—Asthenia—Procarbazine—brain cancer	0.000647	0.00298	CcSEcCtD
Atomoxetine—CYP2C19—endocrine gland—brain cancer	0.000647	0.00219	CbGeAlD
Atomoxetine—Back pain—Temozolomide—brain cancer	0.000646	0.00298	CcSEcCtD
Atomoxetine—Pruritus—Procarbazine—brain cancer	0.000638	0.00294	CcSEcCtD
Atomoxetine—Agitation—Carmustine—brain cancer	0.000635	0.00293	CcSEcCtD
Atomoxetine—Vision blurred—Temozolomide—brain cancer	0.00063	0.0029	CcSEcCtD
Atomoxetine—Tremor—Temozolomide—brain cancer	0.000626	0.00288	CcSEcCtD
Atomoxetine—Somnolence—Hydroxyurea—brain cancer	0.00062	0.00286	CcSEcCtD
Atomoxetine—SLC6A2—central nervous system—brain cancer	0.000619	0.0021	CbGeAlD
Atomoxetine—Diarrhoea—Procarbazine—brain cancer	0.000617	0.00284	CcSEcCtD
Atomoxetine—Dyspepsia—Hydroxyurea—brain cancer	0.000614	0.00283	CcSEcCtD
Atomoxetine—HTR1B—brain—brain cancer	0.000614	0.00208	CbGeAlD
Atomoxetine—Agitation—Temozolomide—brain cancer	0.000614	0.00283	CcSEcCtD
Atomoxetine—Hypoaesthesia—Etoposide—brain cancer	0.000611	0.00282	CcSEcCtD
Atomoxetine—SLC6A3—brain—brain cancer	0.000609	0.00206	CbGeAlD
Atomoxetine—Decreased appetite—Hydroxyurea—brain cancer	0.000607	0.0028	CcSEcCtD
Atomoxetine—Urinary tract disorder—Etoposide—brain cancer	0.000606	0.00279	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000603	0.00278	CcSEcCtD
Atomoxetine—Urethral disorder—Etoposide—brain cancer	0.000602	0.00277	CcSEcCtD
Atomoxetine—Fatigue—Hydroxyurea—brain cancer	0.000602	0.00277	CcSEcCtD
Atomoxetine—Vertigo—Temozolomide—brain cancer	0.0006	0.00277	CcSEcCtD
Atomoxetine—Convulsion—Carmustine—brain cancer	0.000599	0.00276	CcSEcCtD
Atomoxetine—Pain—Hydroxyurea—brain cancer	0.000597	0.00275	CcSEcCtD
Atomoxetine—Constipation—Hydroxyurea—brain cancer	0.000597	0.00275	CcSEcCtD
Atomoxetine—CYP2D6—telencephalon—brain cancer	0.000596	0.00202	CbGeAlD
Atomoxetine—Dizziness—Procarbazine—brain cancer	0.000596	0.00275	CcSEcCtD
Atomoxetine—HTR1D—brain—brain cancer	0.000595	0.00201	CbGeAlD
Atomoxetine—Palpitations—Temozolomide—brain cancer	0.00059	0.00272	CcSEcCtD
Atomoxetine—HTR2C—brain—brain cancer	0.000589	0.00199	CbGeAlD
Atomoxetine—Chest pain—Carmustine—brain cancer	0.000589	0.00271	CcSEcCtD
Atomoxetine—Myalgia—Carmustine—brain cancer	0.000589	0.00271	CcSEcCtD
Atomoxetine—Anxiety—Carmustine—brain cancer	0.000586	0.0027	CcSEcCtD
Atomoxetine—Cough—Temozolomide—brain cancer	0.000583	0.00269	CcSEcCtD
Atomoxetine—Convulsion—Temozolomide—brain cancer	0.000579	0.00267	CcSEcCtD
Atomoxetine—Feeling abnormal—Hydroxyurea—brain cancer	0.000575	0.00265	CcSEcCtD
Atomoxetine—Vomiting—Procarbazine—brain cancer	0.000573	0.00264	CcSEcCtD
Atomoxetine—Cardiac disorder—Etoposide—brain cancer	0.00057	0.00263	CcSEcCtD
Atomoxetine—Flushing—Etoposide—brain cancer	0.00057	0.00263	CcSEcCtD
Atomoxetine—Arthralgia—Temozolomide—brain cancer	0.000569	0.00262	CcSEcCtD
Atomoxetine—Myalgia—Temozolomide—brain cancer	0.000569	0.00262	CcSEcCtD
Atomoxetine—Rash—Procarbazine—brain cancer	0.000569	0.00262	CcSEcCtD
Atomoxetine—Dermatitis—Procarbazine—brain cancer	0.000568	0.00262	CcSEcCtD
Atomoxetine—Anxiety—Temozolomide—brain cancer	0.000567	0.00261	CcSEcCtD
Atomoxetine—Headache—Procarbazine—brain cancer	0.000565	0.0026	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000565	0.0026	CcSEcCtD
Atomoxetine—Infection—Carmustine—brain cancer	0.00056	0.00258	CcSEcCtD
Atomoxetine—SLC6A4—brain—brain cancer	0.000558	0.00189	CbGeAlD
Atomoxetine—Angiopathy—Etoposide—brain cancer	0.000557	0.00257	CcSEcCtD
Atomoxetine—Dry mouth—Temozolomide—brain cancer	0.000556	0.00256	CcSEcCtD
Atomoxetine—Mediastinal disorder—Etoposide—brain cancer	0.000553	0.00255	CcSEcCtD
Atomoxetine—Body temperature increased—Hydroxyurea—brain cancer	0.000552	0.00254	CcSEcCtD
Atomoxetine—Chills—Etoposide—brain cancer	0.000551	0.00254	CcSEcCtD
Atomoxetine—Tachycardia—Carmustine—brain cancer	0.000551	0.00254	CcSEcCtD
Atomoxetine—HTR2A—gonad—brain cancer	0.000546	0.00185	CbGeAlD
Atomoxetine—Nortriptyline—CYP2C9—brain cancer	0.000543	0.0506	CrCbGaD
Atomoxetine—Infection—Temozolomide—brain cancer	0.000542	0.0025	CcSEcCtD
Atomoxetine—Anorexia—Carmustine—brain cancer	0.000538	0.00248	CcSEcCtD
Atomoxetine—Nausea—Procarbazine—brain cancer	0.000536	0.00247	CcSEcCtD
Atomoxetine—Nervous system disorder—Temozolomide—brain cancer	0.000535	0.00246	CcSEcCtD
Atomoxetine—HTR2A—pituitary gland—brain cancer	0.000533	0.0018	CbGeAlD
Atomoxetine—Skin disorder—Temozolomide—brain cancer	0.00053	0.00244	CcSEcCtD
Atomoxetine—Hyperhidrosis—Temozolomide—brain cancer	0.000527	0.00243	CcSEcCtD
Atomoxetine—Dysgeusia—Etoposide—brain cancer	0.000523	0.00241	CcSEcCtD
Atomoxetine—Anorexia—Temozolomide—brain cancer	0.00052	0.00239	CcSEcCtD
Atomoxetine—Back pain—Etoposide—brain cancer	0.000517	0.00238	CcSEcCtD
Atomoxetine—HTR2A—medulla oblongata—brain cancer	0.000514	0.00174	CbGeAlD
Atomoxetine—Musculoskeletal discomfort—Carmustine—brain cancer	0.000514	0.00237	CcSEcCtD
Atomoxetine—Muscle spasms—Etoposide—brain cancer	0.000514	0.00237	CcSEcCtD
Atomoxetine—Insomnia—Carmustine—brain cancer	0.00051	0.00235	CcSEcCtD
Atomoxetine—Paraesthesia—Carmustine—brain cancer	0.000507	0.00233	CcSEcCtD
Atomoxetine—Diphenhydramine—CYP2C9—brain cancer	0.000502	0.0468	CrCbGaD
Atomoxetine—Somnolence—Carmustine—brain cancer	0.000502	0.00231	CcSEcCtD
Atomoxetine—Asthenia—Hydroxyurea—brain cancer	0.000501	0.00231	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000497	0.00229	CcSEcCtD
Atomoxetine—Insomnia—Temozolomide—brain cancer	0.000493	0.00227	CcSEcCtD
Atomoxetine—SLC6A2—brain—brain cancer	0.000491	0.00166	CbGeAlD
Atomoxetine—Decreased appetite—Carmustine—brain cancer	0.00049	0.00226	CcSEcCtD
Atomoxetine—Paraesthesia—Temozolomide—brain cancer	0.00049	0.00226	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Carmustine—brain cancer	0.000487	0.00224	CcSEcCtD
Atomoxetine—Somnolence—Temozolomide—brain cancer	0.000485	0.00223	CcSEcCtD
Atomoxetine—Methadone—CYP2C9—brain cancer	0.000484	0.0452	CrCbGaD
Atomoxetine—Pain—Carmustine—brain cancer	0.000482	0.00222	CcSEcCtD
Atomoxetine—Constipation—Carmustine—brain cancer	0.000482	0.00222	CcSEcCtD
Atomoxetine—Vertigo—Etoposide—brain cancer	0.00048	0.00221	CcSEcCtD
Atomoxetine—Dyspepsia—Temozolomide—brain cancer	0.00048	0.00221	CcSEcCtD
Atomoxetine—Diarrhoea—Hydroxyurea—brain cancer	0.000478	0.0022	CcSEcCtD
Atomoxetine—Decreased appetite—Temozolomide—brain cancer	0.000474	0.00218	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Temozolomide—brain cancer	0.000471	0.00217	CcSEcCtD
Atomoxetine—HTR2A—midbrain—brain cancer	0.00047	0.00159	CbGeAlD
Atomoxetine—Fatigue—Temozolomide—brain cancer	0.00047	0.00217	CcSEcCtD
Atomoxetine—Loss of consciousness—Etoposide—brain cancer	0.00047	0.00217	CcSEcCtD
Atomoxetine—Cough—Etoposide—brain cancer	0.000466	0.00215	CcSEcCtD
Atomoxetine—Constipation—Temozolomide—brain cancer	0.000466	0.00215	CcSEcCtD
Atomoxetine—Pain—Temozolomide—brain cancer	0.000466	0.00215	CcSEcCtD
Atomoxetine—Feeling abnormal—Carmustine—brain cancer	0.000465	0.00214	CcSEcCtD
Atomoxetine—Convulsion—Etoposide—brain cancer	0.000463	0.00213	CcSEcCtD
Atomoxetine—Dizziness—Hydroxyurea—brain cancer	0.000462	0.00213	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Carmustine—brain cancer	0.000461	0.00213	CcSEcCtD
Atomoxetine—HTR2A—spinal cord—brain cancer	0.000459	0.00155	CbGeAlD
Atomoxetine—Chest pain—Etoposide—brain cancer	0.000455	0.0021	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000452	0.00208	CcSEcCtD
Atomoxetine—Feeling abnormal—Temozolomide—brain cancer	0.000449	0.00207	CcSEcCtD
Atomoxetine—Abdominal pain—Carmustine—brain cancer	0.000446	0.00206	CcSEcCtD
Atomoxetine—Body temperature increased—Carmustine—brain cancer	0.000446	0.00206	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Temozolomide—brain cancer	0.000446	0.00205	CcSEcCtD
Atomoxetine—Vomiting—Hydroxyurea—brain cancer	0.000444	0.00204	CcSEcCtD
Atomoxetine—Rash—Hydroxyurea—brain cancer	0.00044	0.00203	CcSEcCtD
Atomoxetine—Dermatitis—Hydroxyurea—brain cancer	0.00044	0.00203	CcSEcCtD
Atomoxetine—Headache—Hydroxyurea—brain cancer	0.000437	0.00201	CcSEcCtD
Atomoxetine—Infection—Etoposide—brain cancer	0.000433	0.002	CcSEcCtD
Atomoxetine—Urticaria—Temozolomide—brain cancer	0.000433	0.002	CcSEcCtD
Atomoxetine—Abdominal pain—Temozolomide—brain cancer	0.000431	0.00199	CcSEcCtD
Atomoxetine—Body temperature increased—Temozolomide—brain cancer	0.000431	0.00199	CcSEcCtD
Atomoxetine—Tachycardia—Etoposide—brain cancer	0.000426	0.00196	CcSEcCtD
Atomoxetine—Skin disorder—Etoposide—brain cancer	0.000424	0.00195	CcSEcCtD
Atomoxetine—Hyperhidrosis—Etoposide—brain cancer	0.000422	0.00194	CcSEcCtD
Atomoxetine—Anorexia—Etoposide—brain cancer	0.000416	0.00192	CcSEcCtD
Atomoxetine—Nausea—Hydroxyurea—brain cancer	0.000415	0.00191	CcSEcCtD
Atomoxetine—HTR2A—endocrine gland—brain cancer	0.000413	0.0014	CbGeAlD
Atomoxetine—HTR2A—head—brain cancer	0.000408	0.00138	CbGeAlD
Atomoxetine—Asthenia—Carmustine—brain cancer	0.000405	0.00187	CcSEcCtD
Atomoxetine—Paraesthesia—Etoposide—brain cancer	0.000392	0.00181	CcSEcCtD
Atomoxetine—Asthenia—Temozolomide—brain cancer	0.000391	0.0018	CcSEcCtD
Atomoxetine—Somnolence—Etoposide—brain cancer	0.000388	0.00179	CcSEcCtD
Atomoxetine—Diarrhoea—Carmustine—brain cancer	0.000386	0.00178	CcSEcCtD
Atomoxetine—Pruritus—Temozolomide—brain cancer	0.000386	0.00178	CcSEcCtD
Atomoxetine—CYP3A4—endocrine gland—brain cancer	0.000382	0.00129	CbGeAlD
Atomoxetine—Decreased appetite—Etoposide—brain cancer	0.000379	0.00175	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Etoposide—brain cancer	0.000377	0.00174	CcSEcCtD
Atomoxetine—CYP2D6—endocrine gland—brain cancer	0.000376	0.00127	CbGeAlD
Atomoxetine—Fatigue—Etoposide—brain cancer	0.000376	0.00173	CcSEcCtD
Atomoxetine—Dizziness—Carmustine—brain cancer	0.000373	0.00172	CcSEcCtD
Atomoxetine—Constipation—Etoposide—brain cancer	0.000373	0.00172	CcSEcCtD
Atomoxetine—Pain—Etoposide—brain cancer	0.000373	0.00172	CcSEcCtD
Atomoxetine—Diarrhoea—Temozolomide—brain cancer	0.000373	0.00172	CcSEcCtD
Atomoxetine—HTR2A—central nervous system—brain cancer	0.000372	0.00126	CbGeAlD
Atomoxetine—CYP2D6—head—brain cancer	0.000371	0.00126	CbGeAlD
Atomoxetine—HTR2A—cerebellum—brain cancer	0.000364	0.00123	CbGeAlD
Atomoxetine—Dizziness—Temozolomide—brain cancer	0.000361	0.00166	CcSEcCtD
Atomoxetine—Feeling abnormal—Etoposide—brain cancer	0.00036	0.00166	CcSEcCtD
Atomoxetine—Vomiting—Carmustine—brain cancer	0.000359	0.00165	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Etoposide—brain cancer	0.000357	0.00164	CcSEcCtD
Atomoxetine—Rash—Carmustine—brain cancer	0.000356	0.00164	CcSEcCtD
Atomoxetine—Dermatitis—Carmustine—brain cancer	0.000355	0.00164	CcSEcCtD
Atomoxetine—Headache—Carmustine—brain cancer	0.000353	0.00163	CcSEcCtD
Atomoxetine—Vomiting—Temozolomide—brain cancer	0.000347	0.0016	CcSEcCtD
Atomoxetine—Urticaria—Etoposide—brain cancer	0.000347	0.0016	CcSEcCtD
Atomoxetine—Abdominal pain—Etoposide—brain cancer	0.000345	0.00159	CcSEcCtD
Atomoxetine—Body temperature increased—Etoposide—brain cancer	0.000345	0.00159	CcSEcCtD
Atomoxetine—CYP3A4—central nervous system—brain cancer	0.000344	0.00117	CbGeAlD
Atomoxetine—Rash—Temozolomide—brain cancer	0.000344	0.00158	CcSEcCtD
Atomoxetine—Dermatitis—Temozolomide—brain cancer	0.000343	0.00158	CcSEcCtD
Atomoxetine—Headache—Temozolomide—brain cancer	0.000342	0.00157	CcSEcCtD
Atomoxetine—CYP2D6—central nervous system—brain cancer	0.000339	0.00115	CbGeAlD
Atomoxetine—Nausea—Carmustine—brain cancer	0.000335	0.00154	CcSEcCtD
Atomoxetine—CYP2D6—cerebellum—brain cancer	0.000331	0.00112	CbGeAlD
Atomoxetine—Nausea—Temozolomide—brain cancer	0.000324	0.00149	CcSEcCtD
Atomoxetine—Asthenia—Etoposide—brain cancer	0.000313	0.00144	CcSEcCtD
Atomoxetine—Pruritus—Etoposide—brain cancer	0.000309	0.00142	CcSEcCtD
Atomoxetine—Diarrhoea—Etoposide—brain cancer	0.000299	0.00138	CcSEcCtD
Atomoxetine—HTR2A—brain—brain cancer	0.000295	0.001	CbGeAlD
Atomoxetine—Dizziness—Etoposide—brain cancer	0.000289	0.00133	CcSEcCtD
Atomoxetine—Vomiting—Etoposide—brain cancer	0.000277	0.00128	CcSEcCtD
Atomoxetine—Rash—Etoposide—brain cancer	0.000275	0.00127	CcSEcCtD
Atomoxetine—Dermatitis—Etoposide—brain cancer	0.000275	0.00127	CcSEcCtD
Atomoxetine—Headache—Etoposide—brain cancer	0.000273	0.00126	CcSEcCtD
Atomoxetine—CYP2D6—brain—brain cancer	0.000269	0.000911	CbGeAlD
Atomoxetine—Nausea—Etoposide—brain cancer	0.000259	0.00119	CcSEcCtD
Atomoxetine—NPY1R—Signaling Pathways—HES1—brain cancer	7.09e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—SHH—brain cancer	7.07e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ABR—brain cancer	6.94e-05	0.00106	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—SHH—brain cancer	6.92e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DTX2—brain cancer	6.89e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TRPC6—brain cancer	6.87e-05	0.00105	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—IL2—brain cancer	6.86e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TRPC6—brain cancer	6.82e-05	0.00104	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PTCH1—brain cancer	6.75e-05	0.00103	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—SMO—brain cancer	6.75e-05	0.00103	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PDGFRA—brain cancer	6.75e-05	0.00103	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PTCH1—brain cancer	6.7e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—SMO—brain cancer	6.7e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TRPC6—brain cancer	6.67e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PTCH1—brain cancer	6.56e-05	0.001	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—SMO—brain cancer	6.56e-05	0.001	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SPP1—brain cancer	6.55e-05	0.000998	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ABR—brain cancer	6.41e-05	0.000976	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ABR—brain cancer	6.36e-05	0.000969	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—brain cancer	6.34e-05	0.000966	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL2—brain cancer	6.23e-05	0.00095	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ABR—brain cancer	6.23e-05	0.000949	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GLI2—brain cancer	6.19e-05	0.000943	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GLI2—brain cancer	6.14e-05	0.000936	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GLI2—brain cancer	6.02e-05	0.000916	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTCH2—brain cancer	6.02e-05	0.000916	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IRS2—brain cancer	5.93e-05	0.000903	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	5.89e-05	0.000898	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HES5—brain cancer	5.83e-05	0.000887	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GLI1—brain cancer	5.82e-05	0.000887	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GLI1—brain cancer	5.78e-05	0.00088	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—brain cancer	5.72e-05	0.000872	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—VAV1—brain cancer	5.67e-05	0.000863	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STRADA—brain cancer	5.66e-05	0.000862	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GLI1—brain cancer	5.66e-05	0.000862	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—VAV1—brain cancer	5.62e-05	0.000857	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—brain cancer	5.58e-05	0.00085	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TRPC6—brain cancer	5.57e-05	0.000848	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SUFU—brain cancer	5.52e-05	0.00084	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—VAV1—brain cancer	5.51e-05	0.000839	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SUFU—brain cancer	5.48e-05	0.000834	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SUFU—brain cancer	5.36e-05	0.000817	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GFAP—brain cancer	5.32e-05	0.000811	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GFAP—brain cancer	5.28e-05	0.000805	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—SHH—brain cancer	5.25e-05	0.000799	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—APC—brain cancer	5.23e-05	0.000797	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PIK3CG—brain cancer	5.23e-05	0.000797	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTCH2—brain cancer	5.22e-05	0.000796	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GFAP—brain cancer	5.17e-05	0.000788	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—VAV1—brain cancer	5.15e-05	0.000784	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—VAV1—brain cancer	5.11e-05	0.000778	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HES5—brain cancer	5.06e-05	0.000771	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TRPC6—brain cancer	5.06e-05	0.000771	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HEY1—brain cancer	5.05e-05	0.000769	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HEY1—brain cancer	5.01e-05	0.000763	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—VAV1—brain cancer	5e-05	0.000762	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTCH1—brain cancer	4.97e-05	0.000758	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—SMO—brain cancer	4.97e-05	0.000758	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DLL1—brain cancer	4.95e-05	0.000754	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STRADA—brain cancer	4.91e-05	0.000748	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DLL1—brain cancer	4.91e-05	0.000748	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HEY1—brain cancer	4.9e-05	0.000747	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TRPC6—brain cancer	4.84e-05	0.000737	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DLL1—brain cancer	4.81e-05	0.000733	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—EGFR—brain cancer	4.77e-05	0.000726	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ABR—brain cancer	4.72e-05	0.000719	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GLI2—brain cancer	4.56e-05	0.000694	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—SHH—brain cancer	4.56e-05	0.000694	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	4.48e-05	0.000682	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TRPC6—brain cancer	4.39e-05	0.000669	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTCH1—brain cancer	4.32e-05	0.000658	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—SMO—brain cancer	4.32e-05	0.000658	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GLI1—brain cancer	4.29e-05	0.000653	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SHH—brain cancer	4.21e-05	0.000641	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SHH—brain cancer	4.18e-05	0.000636	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—VAV1—brain cancer	4.17e-05	0.000636	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ABR—brain cancer	4.1e-05	0.000624	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SHH—brain cancer	4.09e-05	0.000623	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—RELA—brain cancer	4.09e-05	0.000623	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SUFU—brain cancer	4.06e-05	0.000619	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ERBB2—brain cancer	4.06e-05	0.000619	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TRPC6—brain cancer	4.06e-05	0.000618	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TRPC6—brain cancer	4.03e-05	0.000613	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTCH1—brain cancer	3.99e-05	0.000608	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SMO—brain cancer	3.99e-05	0.000608	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTCH1—brain cancer	3.96e-05	0.000603	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GLI2—brain cancer	3.96e-05	0.000603	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SMO—brain cancer	3.96e-05	0.000603	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TRPC6—brain cancer	3.94e-05	0.000601	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GFAP—brain cancer	3.92e-05	0.000597	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	3.89e-05	0.000592	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTCH1—brain cancer	3.88e-05	0.00059	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SMO—brain cancer	3.88e-05	0.00059	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—VAV1—brain cancer	3.79e-05	0.000577	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GLI1—brain cancer	3.72e-05	0.000567	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HEY1—brain cancer	3.72e-05	0.000566	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL2—brain cancer	3.68e-05	0.000561	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DLL1—brain cancer	3.64e-05	0.000555	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—VAV1—brain cancer	3.62e-05	0.000552	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PIK3CG—brain cancer	3.6e-05	0.000548	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCND1—brain cancer	3.59e-05	0.000547	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2C9—brain cancer	3.59e-05	0.000547	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PIK3CG—brain cancer	3.57e-05	0.000544	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CTNNB1—brain cancer	3.56e-05	0.000542	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SUFU—brain cancer	3.53e-05	0.000537	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PIK3CG—brain cancer	3.5e-05	0.000533	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GFAP—brain cancer	3.4e-05	0.000519	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP2C9—brain cancer	3.3e-05	0.000503	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—VAV1—brain cancer	3.29e-05	0.000501	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PIK3CG—brain cancer	3.27e-05	0.000498	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PIK3CG—brain cancer	3.24e-05	0.000494	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HEY1—brain cancer	3.23e-05	0.000492	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOTCH2—brain cancer	3.19e-05	0.000486	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PIK3CG—brain cancer	3.18e-05	0.000484	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOTCH2—brain cancer	3.16e-05	0.000482	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DLL1—brain cancer	3.16e-05	0.000482	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VEGFA—brain cancer	3.13e-05	0.000477	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—STAT3—brain cancer	3.1e-05	0.000472	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOTCH2—brain cancer	3.1e-05	0.000472	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SHH—brain cancer	3.1e-05	0.000472	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—BSG—brain cancer	3.05e-05	0.000465	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VAV1—brain cancer	3.04e-05	0.000463	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VAV1—brain cancer	3.02e-05	0.00046	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TRPC6—brain cancer	2.99e-05	0.000455	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VAV1—brain cancer	2.95e-05	0.00045	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SMO—brain cancer	2.94e-05	0.000447	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTCH1—brain cancer	2.94e-05	0.000447	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MYC—brain cancer	2.88e-05	0.000439	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EGFR—brain cancer	2.82e-05	0.000429	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—BSG—brain cancer	2.81e-05	0.000428	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SHH—brain cancer	2.69e-05	0.00041	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CG—brain cancer	2.65e-05	0.000404	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—IDH1—brain cancer	2.62e-05	0.0004	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HES1—brain cancer	2.61e-05	0.000398	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TRPC6—brain cancer	2.59e-05	0.000395	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HES1—brain cancer	2.59e-05	0.000395	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SMO—brain cancer	2.55e-05	0.000389	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTCH1—brain cancer	2.55e-05	0.000389	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HES1—brain cancer	2.54e-05	0.000387	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL2—brain cancer	2.53e-05	0.000386	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL2—brain cancer	2.51e-05	0.000383	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PDGFRA—brain cancer	2.49e-05	0.000379	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PDGFRA—brain cancer	2.47e-05	0.000376	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL2—brain cancer	2.46e-05	0.000375	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PDGFRA—brain cancer	2.42e-05	0.000368	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SPP1—brain cancer	2.42e-05	0.000368	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—IDH1—brain cancer	2.41e-05	0.000368	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CG—brain cancer	2.41e-05	0.000367	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SPP1—brain cancer	2.4e-05	0.000365	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—brain cancer	2.36e-05	0.00036	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SPP1—brain cancer	2.35e-05	0.000358	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOTCH2—brain cancer	2.35e-05	0.000358	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CG—brain cancer	2.3e-05	0.000351	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL2—brain cancer	2.3e-05	0.00035	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL2—brain cancer	2.28e-05	0.000348	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VAV1—brain cancer	2.24e-05	0.000341	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL2—brain cancer	2.23e-05	0.00034	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IRS2—brain cancer	2.19e-05	0.000333	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IRS2—brain cancer	2.17e-05	0.00033	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2C9—brain cancer	2.16e-05	0.000329	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.14e-05	0.000325	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IRS2—brain cancer	2.12e-05	0.000324	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CG—brain cancer	2.09e-05	0.000318	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ENO2—brain cancer	2.07e-05	0.000316	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOTCH2—brain cancer	2.04e-05	0.000311	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VAV1—brain cancer	1.94e-05	0.000296	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CG—brain cancer	1.93e-05	0.000294	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APC—brain cancer	1.93e-05	0.000294	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HES1—brain cancer	1.93e-05	0.000293	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APC—brain cancer	1.92e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CG—brain cancer	1.92e-05	0.000292	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ENO2—brain cancer	1.91e-05	0.000291	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CG—brain cancer	1.88e-05	0.000286	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APC—brain cancer	1.88e-05	0.000286	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—brain cancer	1.86e-05	0.000284	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BSG—brain cancer	1.84e-05	0.00028	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PDGFRA—brain cancer	1.83e-05	0.000279	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SPP1—brain cancer	1.78e-05	0.000271	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—brain cancer	1.76e-05	0.000268	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—brain cancer	1.75e-05	0.000266	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—brain cancer	1.71e-05	0.00026	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—brain cancer	1.69e-05	0.000258	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HES1—brain cancer	1.67e-05	0.000255	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—brain cancer	1.62e-05	0.000247	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IRS2—brain cancer	1.61e-05	0.000245	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDGFRA—brain cancer	1.59e-05	0.000243	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—IDH1—brain cancer	1.58e-05	0.00024	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SPP1—brain cancer	1.55e-05	0.000235	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RELA—brain cancer	1.51e-05	0.00023	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB2—brain cancer	1.5e-05	0.000228	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RELA—brain cancer	1.5e-05	0.000228	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB2—brain cancer	1.49e-05	0.000227	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—brain cancer	1.47e-05	0.000224	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RELA—brain cancer	1.47e-05	0.000223	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB2—brain cancer	1.46e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CG—brain cancer	1.42e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APC—brain cancer	1.42e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IRS2—brain cancer	1.4e-05	0.000213	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—brain cancer	1.36e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—brain cancer	1.35e-05	0.000205	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—brain cancer	1.32e-05	0.000202	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—brain cancer	1.32e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—brain cancer	1.31e-05	0.0002	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CTNNB1—brain cancer	1.31e-05	0.0002	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CTNNB1—brain cancer	1.3e-05	0.000198	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—brain cancer	1.3e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—brain cancer	1.29e-05	0.000196	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CTNNB1—brain cancer	1.27e-05	0.000194	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO2—brain cancer	1.25e-05	0.00019	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—brain cancer	1.23e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APC—brain cancer	1.23e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—brain cancer	1.15e-05	0.000176	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—brain cancer	1.15e-05	0.000175	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—brain cancer	1.14e-05	0.000174	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—brain cancer	1.13e-05	0.000173	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—brain cancer	1.12e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—brain cancer	1.12e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RELA—brain cancer	1.11e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—brain cancer	1.11e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—brain cancer	1.1e-05	0.000168	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—brain cancer	1.06e-05	0.000162	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—brain cancer	1.05e-05	0.000161	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—brain cancer	1.04e-05	0.000158	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—brain cancer	1.03e-05	0.000157	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—brain cancer	1.03e-05	0.000157	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—brain cancer	1.01e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—brain cancer	1e-05	0.000152	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—brain cancer	9.75e-06	0.000149	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CTNNB1—brain cancer	9.66e-06	0.000147	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RELA—brain cancer	9.65e-06	0.000147	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—brain cancer	9.59e-06	0.000146	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—brain cancer	9.52e-06	0.000145	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—brain cancer	8.75e-06	0.000133	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—brain cancer	8.72e-06	0.000133	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—brain cancer	8.69e-06	0.000132	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—brain cancer	8.66e-06	0.000132	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—brain cancer	8.5e-06	0.00013	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—brain cancer	8.48e-06	0.000129	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—brain cancer	8.47e-06	0.000129	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—brain cancer	8.42e-06	0.000128	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CTNNB1—brain cancer	8.39e-06	0.000128	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—brain cancer	7.82e-06	0.000119	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—brain cancer	7.65e-06	0.000117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—brain cancer	7.38e-06	0.000112	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—brain cancer	7.31e-06	0.000111	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—brain cancer	6.79e-06	0.000103	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—brain cancer	6.64e-06	0.000101	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—brain cancer	6.42e-06	9.79e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—brain cancer	5.72e-06	8.72e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—brain cancer	5.58e-06	8.5e-05	CbGpPWpGaD
